uploads///dna _

What Analysts Recommend for Boston Scientific and Abbott

By

Feb. 20 2019, Published 8:04 a.m. ET

Stock price movements

On February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its 52-week high of $40.33. Its market capitalization was $55.24 billion, and its trailing-12-month and forward PE ratios are 33.74x and 22.18x, respectively.

Since its fourth-quarter earnings release on February 6, Boston Scientific stock has increased by 5.65% from $37.75 on February 5 to $40.01 on February 15. The company surpassed its consensus EPS estimate by $0.03 in the fourth quarter.

Article continues below advertisement

On February 15, Abbott Laboratories (ABT) closed at $75.25, 1.73% higher than its previous closing price, 32.46% higher than its 52-week low of $56.81, and 0.03% below its 52-week high of $75.27. Its market capitalization was $132.41 billion, and its trailing-12-month and forward PE ratios are 53.90x and 20.91x, respectively.

Since its fourth-quarter earnings release on January 23, Abbott Laboratories stock rose by 5.26% from $71.49 on January 22 to $75.25 on February 15. The company surpassed its consensus revenue estimate by $40 million. Boston Scientific is trading at a lower trailing PE ratio but a higher forward PE ratio as compared to Abbott Laboratories.

Analysts’ recommendations and target price

The 12-month consensus recommendation for Boston Scientific and Abbott Laboratories is a “strong buy” and a “buy,” respectively. Of the 24 analysts covering Boston Scientific, 15 recommend a “strong buy,” seven recommend a “buy,” and two recommend a “hold.” Their 12-month target price is $43.8, 9.47% higher than its last closing price on February 15. The highest target price estimate for the company is $48, and the lowest is $39.5.

On the other hand, eight analysts rated Abbott Laboratories as a “strong buy,” 11 have rated it as a “buy,” while only two have rated the company as a “hold.” Analysts’ 12-month target price for Abbott Laboratories is $80.08, 6.42% higher than its last closing price on February 15. The highest and the lowest target price estimate for the company is $86 and $70, respectively.

Next, we’ll look at the revenue growth trajectory of Boston Scientific and Abbott Laboratories in greater detail.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.